GlaxoSmithKline and AFFiRiS Ink Alzheimer’s Disease Vaccine Deal

This post was commissioned on October 23, 2008, and it was categorized as License/Partnership.

Feel free to leave a comment below. Eben loves comments. You may also subscribe to comments through this RSS Comments feed or trackback here.

GlaxoSmithKline Biologicals and AFFiRiS GmbH announced the execution of a collaboration agreement granting GSK exclusive rights to AFFiRiS’s Alzheimer’s disease vaccine programmes, aimed at treating Alzheimer’s by targeting beta-amyloid.

As part of the agreement, GSK is acquiring exclusive rights to develop and commercialise two Alzheimer’s disease vaccine candidates that are based on AFFiRiS AFFiTOPE technology and are currently in Phase I clinical development. AFFiRiS is also granting GSK an exclusive option to develop and commercialise alternative Alzheimer’s disease vaccine candidates which are in preclinical development.

Terms
————————————————-
Upfront: €22.5 million ($29 million)
Milestones: €407.5 million ($523 million)
————————————————-

Nice chunk of change. I’m not personally a big believer in Alzheimer’s disease vaccines in general (or these APP/tau approaches) but I’ve been wrong before and I guess covering your bases for ~$29M is a fine strategy if you have the money.

Eventually though, one of these gamma secretase/APP/tau based approaches to treating or, in this case, preventing AD better show at least a shred of efficacy in clinical trials or some poor licensing professional is getting fired at pretty much every major pharma company. Sheep.

GlaxoSmithKline and AFFiRiS sign an exclusive licence and option agreement for therapeutic Alzheimer’s disease candidate vaccines
-(Via GSK news.)

Theoretically Related Posts

February 6, 2009 -- Idenix Take $34M Upfront From GSK For IDX899 (0)
September 10, 2008 -- GSK and Cellzome Announce Alliance over Kinase Technology (0)
April 25, 2008 -- Astellas Pharma and CoMentis Sign $760M Alzheimer’s Deal (1)
March 27, 2008 -- Top Biopharma Deals Q1 ‘08 (0)
December 17, 2008 -- GlaxoSmithKline and Dynavax announce worldwide strategic alliance (0)
December 12, 2008 -- BMS Drops 240M For Codevelopment of 2 Exelixis Cancer Drugs (1)
November 24, 2008 -- Exelixis and Bristol-Myers Squibb to Co-Develop a Selective Cdc7 Inhibitor (2)
October 30, 2008 -- GlaxoSmithKline to acquires Genelabs Technologies for $57M (0)
October 24, 2008 -- Forest Laboratories, Inc. and Phenomix Corporation in $340 Million Diabetes Deal (0)
October 22, 2008 -- Archer Pharmaceuticals Launches to Target Alzheimer’s Disease (0)

This post was constructed by

Eben Tessari

.

Eben is a highly caffeinated business development associate at a small, cash sensitive pharmaceutical company somewhere in Massachusetts. He enjoys cliche-less banter, compartmentalization, non-equilibrium thermodynamics and NPV analysis. Agree or disagree with what he's posted? He encourages comments.

If one were so inclined, one could follow him at any of these fine web 2.0 establishments: